Healthcare >> CEO Interviews >> April 28, 2003
President and CEO of Caprion since 1998, LLOYD M. SEGAL has
presided over Caprion's growth to more than 80 people, and key
alliances, including IDEC Pharmaceuticals, Johnson &
Johnson/Ortho-Clinical Diagnostics, IDEXX Laboratories,
Micromass/Waters Corp. and Sun Microsystems. He has led private
financings for the company totaling over $100 million in equity
and debt capital. He was previously a management consultant with
McKinsey & Co., and served as President and CEO of Advanced
Bioconcept Ltd. (ABL) from 1996 to 1998, during which he led the
sale of ABL to NEN Life Sciences (now PerkinElmer). He is a
member of the Board of Directors of SciQuest (NASDAQ:SQST) and a
member of the Board of Overseers of the School of Science,
Brandeis University. He earned a BA in Politics from Brandeis
University (Boston) and an MBA from Harvard Business School
(Cambridge). Profile
Pharmaceuticals?
Mr. Segal: Caprion is in the business of looking at specific
proteomes of interest in disease or understanding the
